logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report

O'Brien DP, Athan E, Hughes AJ, Johnson PD
2008-06-01 • Journal of Medical Case Reports
2008-06-01 • Journal of Medical Case Reports
ABSTRACT: INTRODUCTION: Treatment for osteomyelitis-complicating Mycobacterium ulcerans infection typically requires extensive surgery and even amputation, with no reported benefit from ...
Journal Article
|
Research

Mycobacterium Ulcerans Treatment – Can Antibiotic Duration Be Reduced in Selected Patients? (D/N include in MSF Publications analysis)

Cowan R, Athan E, Friedman ND, Hughes AJ, McDonald AH,  et al.
2015-02-06 • PLOS Neglected Tropical Diseases
2015-02-06 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

Guglielmetti L, Hewison CCH, Avaliani Z, Hughes AJ, Kiria N,  et al.
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...
Journal Article
|
Research

Mycobacterium ulcerans treatment - can antibiotic duration be reduced in selected patients?

Cowan R, Athan E, Friedman ND, Hughes AJ, McDonald AH,  et al.
2015-02-06 • PLOS Neglected Tropical Diseases
2015-02-06 • PLOS Neglected Tropical Diseases
INTRODUCTION
Mycobacterium ulcerans (M. ulcerans) is a necrotizing skin infection endemic to the Bellarine Peninsula, Australia. Current treatment recommendations include 8 weeks of ...